Status: Not yet recruiting
Phase 1b Clinical Study in Patients With Active Ulcerative Colitis
Purpose of study is to evaluate the safety, tolerability, pharmacokinetics of TP317 vs. placebo in adults with active ulcerative colitis. Participants will be randomly assigned to receive either daily oral tablets (8 tablets) of TP317 (80 mg) or an identical placebo pill. Study will include 2 colonoscopies, daily dosing (including at home and in clinic), safety assessments, diary and questionnaire completion and 5 in clinic visits.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Thetis Pharmaceuticals LLCUpdated: Sep 22, 2026
Eligibility criteria
Diagnosis of UC with disease duration of at least 12 weeks prior to randomizatio... [+10]
Likeliness to require hospitalization for medical care or surgical intervention... [+10]